Niagen Bioscience (NASDAQ:NAGE) Upgraded to “Strong-Buy” at Freedom Capital

Freedom Capital upgraded shares of Niagen Bioscience (NASDAQ:NAGE) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Tuesday, April 21st. Canaccord Genuity Group dropped their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Wall Street Zen downgraded shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, HC Wainwright restated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $10.50.

Niagen Bioscience Trading Down 2.3%

NASDAQ:NAGE opened at $3.37 on Monday. The business’s 50-day moving average is $3.70 and its 200 day moving average is $4.79. Niagen Bioscience has a 12 month low of $3.17 and a 12 month high of $12.41. The company has a market capitalization of $268.39 million, a P/E ratio of 16.05 and a beta of 2.09.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $31.47 million during the quarter. Niagen Bioscience had a return on equity of 22.68% and a net margin of 14.29%. On average, research analysts forecast that Niagen Bioscience will post 0.22 earnings per share for the current year.

Institutional Investors Weigh In On Niagen Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth about $37,522,000. SteelPeak Wealth LLC bought a new stake in Niagen Bioscience in the first quarter worth about $14,875,000. Arrowstreet Capital Limited Partnership lifted its stake in Niagen Bioscience by 47.1% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after purchasing an additional 761,685 shares during the last quarter. UBS Group AG boosted its position in shares of Niagen Bioscience by 18.0% during the fourth quarter. UBS Group AG now owns 1,411,742 shares of the company’s stock valued at $8,979,000 after buying an additional 215,645 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Niagen Bioscience by 45.4% during the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock valued at $5,860,000 after buying an additional 414,725 shares during the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.